Data as of Nov 26
| +2.64 / +5.82%|
The 5 analysts offering 12-month price forecasts for Enanta Pharmaceuticals Inc have a median target of 45.00, with a high estimate of 53.00 and a low estimate of 41.00. The median estimate represents a -6.23% decrease from the last price of 47.99.
The current consensus among 6 polled investment analysts is to Buy stock in Enanta Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.